4-Methoxy-2-aminobenzothiazole (MABT), systematically named 4-methoxy-1,3-benzothiazol-2-amine, is supplied as a crystalline free base with a molecular weight of 180.23 g·mol⁻¹. Manufactured under cGMP for pharmaceutical intermediate service, the compound is routinely controlled to a purity of ≥ 98.5% (HPLC, area%) with a single dominant impurity—the 5-methoxy positional isomer—held below 0.8%. The methoxy substitution at position 4 introduces an electron-donating effect that differentiates it sharply from the parent 2-aminobenzothiazole scaffold, shifting the pKa of the conjugate acid by approximately +0.4 units and altering regioselectivity in electrophilic aromatic substitution. These modifications render MABT a key building block in kinase inhibitor programmes where the methoxy oxygen participates in a hydrogen-bonding network with the hinge region of the ATP-binding pocket, a binding mode not accessible to the unsubstituted analogue.
What Distinguishes 4-Methoxy-2-Aminobenzothiazole from 2-Aminobenzothiazole in Heterocyclic Amine Reactivity?
In comparative reactivity studies run under Buchwald–Hartwig amination conditions (Pd₂(dba)₃ / Xantphos, t-BuONa, toluene, 90 °C), MABT undergoes N‑arylation with 4-bromobenzotrifluoride at an initial rate 1.7 times that of 2-aminobenzothiazole. The rate enhancement arises from the +M effect of the methoxy group, which raises the electron density on the endocyclic nitrogen and stabilises the palladium-amido intermediate. Concomitantly, the competing C‑2 oxidative addition pathway observed with 2-aminobenzothiazole in the presence of electron‑poor aryl halides is suppressed when the 4‑OCH₃ group is present; residual C‑2 coupling product remains below 0.3% as determined by LC‑MS (SIM m/z 165). The data were obtained on 5‑L jacketed glass reactors with anchor‑type agitation and traced against an internal reference standard conforming to general chapter Ph. Eur. 2.2.29.
| Parameter | Value | Method |
|---|---|---|
| Appearance | Off‑white to pale yellow crystalline powder | Visual / Ph. Eur. 2.2.1 |
| Melting interval | 131.2–134.6 °C | USP 〈741〉, capillary |
| Assay (anhydrous, solvent‑free basis) | 99.1% w/w | HPLC external standard, Ph. Eur. 2.2.46 |
| Water (Karl Fischer) | 0.12% | USP 〈921〉 Method Ia |
| Residue on ignition | 0.04% | USP 〈281〉 |
| Sulfated ash | 0.06% | Ph. Eur. 2.4.14 |
| Heavy metals | ≤ 10 ppm | USP 〈232〉/〈233〉 |
| Total related substances | 0.65% | HPLC gradient, Ph. Eur. 2.2.29 |
During pilot‑scale crystallisation from 2‑propanol/water (3:1 v/v), the 5‑methoxy isomer co‑precipitates if the cooling ramp exceeds 0.4 °C·min⁻¹ through the metastable zone between 58 °C and 43 °C. Orthogonal seeding with 0.05% w/w of pure MABT seed crystals of D₅₀ < 45 µm (Malvern Mastersizer) is mandatory when the batch size exceeds 50 kg to avoid oiling‑out. The isolated cake is dried under full vacuum (<10 mbar) at 45 °C for 16 h; residual 2‑propanol is monitored by headspace GC‑FID and kept below 500 ppm in conformance with ICH Q3C options for Class 3 solvents.
When Residual Sulfolane from Synthesis Exceeds 50 ppm in Downstream Coupling Reactions
In the widely practised cyclisation route that employs sulfolane as a high‑boiling dipolar aprotic solvent, incomplete removal of the carry‑over solvent poisons palladium catalysts in subsequent cross‑coupling steps. At a sulfolane level of 62 ppm in the MABT feed, the turnover number for the Sonogashira coupling with ethynyltrimethylsilane falls by 42% relative to a sulfolane‑free control (catalyst loading 0.25 mol% PdCl₂(PPh₃)₂, CuI 0.5 mol%, Et₃N, DMF, 50 °C). The inhibitory effect is attributed to sulfolane’s high σ‑donor capacity, which displaces the labile phosphine ligand and blocks the active metal centre. Consequently, the acceptance specification for MABT destined for transition‑metal‑mediated library synthesis caps sulfolane at 25 ppm (quantified by GC‑MS with single‑ion monitoring at m/z 120). The loading specification is verified for every drum using a single‑quadrupole GC‑MS system equipped with a 30 m × 0.25 mm 5%‑phenyl‑methylpolysiloxane column and a programmed oven ramp from 60 °C to 280 °C at 15 °C·min⁻¹.
Handling of MABT requires local exhaust ventilation and nitrile gloves; the dust is weakly irritating to mucous membranes. The compound is packaged under argon in amber glass bottles or HDPE pails with PET‑aluminium‑PE laminated liners to prevent photodegradation. Retest dating is set at 24 months when stored between 2–8 °C.
In the development of benzothiazole‑based azo disperse dyes, MABT serves as a diazo component that yields a bathochromic shift of 18–22 nm relative to the analogous dye prepared from 2‑aminobenzothiazole, measured in DMF at 5×10⁻⁵ mol·L⁻¹. The methoxy group improves solubility in the dye‑bath to 12 g·L⁻¹ at 80 °C, versus 7 g·L⁻¹ for the unsubstituted derivative, enabling application without anionic dispersant loadings that would otherwise exceed 2 g·L⁻¹—a threshold where aggregation and filter‑blocking become prevalent on high‑pressure HT beam dyeing machines (Thies iZi‑flex, 140 °C). The build‑up on polyester reaches g·kg⁻¹ at 2% omf within 45 min under superatmospheric conditions, with L* and b* colour‑fastness to light rated at ISO 105‑B02:2014 grades 6–7.
Vulcanization Accelerator Intermediate: Curing Kinetics and Scorch Safety Profiles
When MABT is elaborated into a sulfenamide accelerator—for instance, N‑cyclohexyl‑4‑methoxy‑2‑benzothiazolesulfenamide—the methoxy substituent induces a measurable delay in scorch time compared with the conventional accelerator 2‑mercaptobenzothiazole (MBT)‑derived sulfenamides. In a natural rubber formulation (SMR CV60 100 phr, N‑330 carbon black 50 phr, zinc oxide 5 phr, stearic acid 2 phr, sulfur 2 phr, accelerator equimolar to 0.8 phr MBT), the Mooney scorch time at 121 °C (ASTM D1646‑19a) increases from 28.4 min to 34.8 min when the 4‑methoxy derivative replaces the unsubstituted analogue at an equivalent molar loading. The cure curve obtained with an oscillating disc rheometer (ASTM D2084‑19) shows t90 extended by 1.4 min while maintaining a crosslink density within 5% of the control, as evidenced by the difference in maximum torque (MH–ML). The rate advantage becomes significant on continuous vulcanisation lines where an extra 1.2‑min processing safety window reduces reject rates from premature scorching by an estimated 3.2 percentage points on a production volume of 800 tonnes·year⁻¹.
In contrast to MBT and its direct derivatives, the 4‑methoxy‑2‑amino precursor itself is not used as a primary accelerator; its weakly basic amine functionality provides negligible activation of elemental sulfur. Instead, its value lies in the downstream sulfenamide architecture, where the methoxy group moderates the electron‑withdrawing nature of the benzothiazole ring and retards the cleavage of the S–N bond, thereby shifting the onset of crosslinking without sacrificing final network density.
| Compound | Water solubility (mg·L⁻¹) | Solubility in ethanol (mg·mL⁻¹) | pKa (conjugate acid) | Log P (octanol‑water, shake‑flask) |
|---|---|---|---|---|
| 2‑Aminobenzothiazole | 980 | 36 | 4.02 ± 0.03 | 1.49 |
| 4‑Methoxy‑2‑aminobenzothiazole | 880 | 45 | 4.44 ± 0.04 | 1.64 |
| 6‑Methoxy‑2‑aminobenzothiazole | 1,020 | 41 | 4.27 ± 0.03 | 1.53 |
| 4‑Chloro‑2‑aminobenzothiazole | 675 | 28 | 3.86 ± 0.05 | 1.95 |
Isocratic HPLC‑PDA Purity Method for Release Testing
For quality control, the release assay is performed on a 150 mm × 4.6 mm column packed with octadecylsilane (L1, 3 µm) at 30 °C. The mobile phase consists of acetonitrile and 25 mM potassium dihydrogen phosphate buffer adjusted to pH 2.8 with phosphoric acid (40:60 v/v), delivered at a flow rate of 1.0 mL·min⁻¹. The injection volume is 10 µL of a 0.5 mg·mL⁻¹ solution in diluent (water‑acetonitrile, 50:50). Detection at 254 nm with a photodiode‑array range of 210–400 nm allows simultaneous peak‑purity evaluation. Under these conditions, the retention time for MABT is 7.2 ± 0.1 min, while the 5‑methoxy isomer elutes at 8.5 min with baseline resolution > 2.5. System suitability criteria require theoretical plates N > 12,000 and tailing factor 0.95–1.05, verified with a 5‑µL injection of system suitability solution prepared according to Ph. Eur. general text 5.16. The method is linear over the range 0.05–150% of the nominal concentration (r² ≥ 0.9998), with a limit of quantification of 0.02% relative to the principal peak.
Preparative chromatography can remove the 5‑methoxy isomer with a discrimination factor of 2.3. On a 10‑cm‑diameter dynamic axial compression column packed with 10 µm C18 stationary phase and eluted with a methanol‑water‑acetic acid (55:44.8:0.2) mobile phase, a feed containing 1.8% of the isomer yields a heart‑cut fraction with isomer content reduced to 0.15% and recovery of the desired product at 94%. The collected acetonitrile‑containing fraction must be concentrated below 35 °C using a wiped‑film evaporator to avoid retro‑Mannich degradation that has been observed when pot temperatures exceed 40 °C under prolonged hold‑up.
Long‑term stability studies (ICH Q1A(R2), 25 °C/60% RH and 40 °C/75% RH) confirm that MABT packed in the recommended barrier packaging shows no significant change in assay or impurity profile over 24 months. The major degradation product, detected at levels ≤ 0.08% after 36 months at accelerated conditions, has been identified by HRMS‑MS as the 4‑demethylated catechol analogue, which is controlled by the sulfated‑ash specification. This degradation pathway does not affect the specification‑compliant material within the assigned retest interval.
